Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Roth 15th Annual London Conference, which will be held at the Four Seasons Hotel London at Park Lane in London, UK on June 24-26, 2025.
Niagen Bioscience CFO, Ozan Pamir, will attend in-person one-on-one meetings with institutional investors throughout the conference.
To learn more and submit a registration request, visit https://ibn.fm/RothLondon2025.
For additional information on Niagen Bioscience, visit www.niagenbioscience.com.
About Niagen Bioscience:
Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.
The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.
Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age.
At the heart of its clinically proven product portfolio is Niagen (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen, the number one NAD+ boosting oral supplement in the United States (available at www.truniagen.com), and Niagen Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.
Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.
Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 12/31/2024).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250620340838/en/
Contacts:
Niagen Bioscience Media Contact:
Kendall Knysch, Senior Director of Media Relations Partnerships
310.405.5227
kendall.knysch@niagenbio.com
Niagen Bioscience Investor Relations Contact:
ICR, LLC
Reed Anderson
(646) 277-1260
Stephanie Carrington
(646) 277-1282
niagenir@icrinc.com
